Eli Lilly LLY releases its next round of earnings this Tuesday, July 30. Here's Benzinga's essential guide to Eli Lilly's Q2 earnings report.
Earnings and Revenue
Eli Lilly earnings will be near $1.45 per share on sales of $5.59 billion, according to analysts.
Eli Lilly earnings in the same period a year ago was $1.50. Quarterly sales came in at $6.36 billion. The Wall Street consensus estimate for earnings would represent a 3.33% decrease for the company. Sales would have fallen 12.04% from the same quarter last year. Eli Lilly's reported EPS has stacked up against analyst estimates in the past like this:
Quarter | Q1 2019 | Q4 2018 | Q3 2018 | Q2 2018 |
EPS Estimate | 1.260 | 1.35 | 1.36 | 1.3 |
EPS Actual | 1.330 | 1.33 | 1.39 | 1.5 |
Stock Performance
Shares of Eli Lilly were trading at $108.27 as of July 26. Over the last 52-week period, shares are up 13.75%. Given that these returns are generally positive, long-term shareholders are probably happy going into this earnings release.
Analyst estimates have adjusted lower for EPS and revenues over the past 90 days. Analysts generally rate Eli Lilly stock as Neutral. The strength of this rating has maintained conviction over the past three months.
Conference Call
Don't be surprised to see the stock move on comments made during its conference call. Eli Lilly is scheduled to hold the call at 9:00 a.m. ET and can be accessed here: https://investor.lilly.com/webcasts-and-presentations
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.